JP4439262B2 - 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用 - Google Patents

操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用 Download PDF

Info

Publication number
JP4439262B2
JP4439262B2 JP2003529974A JP2003529974A JP4439262B2 JP 4439262 B2 JP4439262 B2 JP 4439262B2 JP 2003529974 A JP2003529974 A JP 2003529974A JP 2003529974 A JP2003529974 A JP 2003529974A JP 4439262 B2 JP4439262 B2 JP 4439262B2
Authority
JP
Japan
Prior art keywords
template
primer
polynucleotide
sequence
annealing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003529974A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005503802A5 (enExample
JP2005503802A (ja
Inventor
キャサリン エス． ボウディッシュ，
シャナ フレデリックソン，
トシアキ マルヤマ，
イン−チー リン
マーク レンシャウ，
Original Assignee
アレクシオン ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アレクシオン ファーマシューティカルズ， インコーポレイテッド filed Critical アレクシオン ファーマシューティカルズ， インコーポレイテッド
Publication of JP2005503802A publication Critical patent/JP2005503802A/ja
Publication of JP2005503802A5 publication Critical patent/JP2005503802A5/ja
Application granted granted Critical
Publication of JP4439262B2 publication Critical patent/JP4439262B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6853—Nucleic acid amplification reactions using modified primers or templates
    • C12Q1/6855—Ligating adaptors

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Control Of Amplification And Gain Control (AREA)
  • Saccharide Compounds (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Adhesives Or Adhesive Processes (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
JP2003529974A 2001-09-19 2002-09-19 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用 Expired - Fee Related JP4439262B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32345501P 2001-09-19 2001-09-19
PCT/US2002/029889 WO2003025202A2 (en) 2001-09-19 2002-09-19 Engineered templates and their use in single primer amplification

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009016031A Division JP5107274B2 (ja) 2001-09-19 2009-01-27 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用

Publications (3)

Publication Number Publication Date
JP2005503802A JP2005503802A (ja) 2005-02-10
JP2005503802A5 JP2005503802A5 (enExample) 2006-01-05
JP4439262B2 true JP4439262B2 (ja) 2010-03-24

Family

ID=23259271

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003529974A Expired - Fee Related JP4439262B2 (ja) 2001-09-19 2002-09-19 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用
JP2009016031A Expired - Fee Related JP5107274B2 (ja) 2001-09-19 2009-01-27 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009016031A Expired - Fee Related JP5107274B2 (ja) 2001-09-19 2009-01-27 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用

Country Status (12)

Country Link
US (1) US7306906B2 (enExample)
EP (1) EP1436404B1 (enExample)
JP (2) JP4439262B2 (enExample)
AT (1) ATE448320T1 (enExample)
AU (1) AU2002341752B2 (enExample)
CA (1) CA2460639C (enExample)
CY (1) CY1109828T1 (enExample)
DE (1) DE60234369D1 (enExample)
DK (1) DK1436404T3 (enExample)
ES (1) ES2336433T3 (enExample)
PT (1) PT1436404E (enExample)
WO (1) WO2003025202A2 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7427665B2 (en) 2000-12-08 2008-09-23 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002048401A2 (en) 2000-12-11 2002-06-20 Alexion Pharmaceuticals, Inc. Nested oligonucleotides containing hairpin for nucleic acid amplification
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7414111B2 (en) * 2001-09-19 2008-08-19 Alexion Pharmaceuticals, Inc. Engineered templates and their use in single primer amplification
US7593483B2 (en) * 2004-05-07 2009-09-22 Broadcom Corporation Nonlinear mapping in digital-to-analog and analog-to-digital converters
EP2290073A3 (en) * 2004-05-28 2011-08-31 Asuragen, Inc. Methods and compositions involving microRNA
US20060078894A1 (en) * 2004-10-12 2006-04-13 Winkler Matthew M Methods and compositions for analyzing nucleic acids
CA2857878A1 (en) 2004-11-12 2006-12-28 Asuragen, Inc. Methods and compositions involving mirna and mirna inhibitor molecules
EP1929045B9 (en) * 2005-09-06 2012-06-20 Gen-Probe Incorporated Methods, compositions and kits for isothermal amplification of nucleic acids
US8075884B2 (en) 2006-01-12 2011-12-13 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
EP2013366B1 (en) * 2006-05-01 2016-11-30 Siemens Healthcare Diagnostics Inc. Sequencing of the L10 codon of the HIV gag gene
JP2010510964A (ja) * 2006-09-19 2010-04-08 アシュラジェン インコーポレイテッド 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路
US20080131878A1 (en) * 2006-12-05 2008-06-05 Asuragen, Inc. Compositions and Methods for the Detection of Small RNA
WO2008073919A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-20 regulated genes and pathways as targets for therapeutic intervention
WO2008073920A2 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Mir-21 regulated genes and pathways as targets for therapeutic intervention
CN101622348A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为治疗性干预靶标的miR-20调节的基因和途径
CA2671299A1 (en) * 2006-12-08 2008-06-19 Asuragen, Inc. Functions and targets of let-7 micro rnas
US20090175827A1 (en) * 2006-12-29 2009-07-09 Byrom Mike W miR-16 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
US20090232893A1 (en) * 2007-05-22 2009-09-17 Bader Andreas G miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION
CA2689974A1 (en) * 2007-06-08 2008-12-18 Asuragen, Inc. Mir-34 regulated genes and pathways as targets for therapeutic intervention
US8986684B2 (en) 2007-07-25 2015-03-24 Alexion Pharmaceuticals, Inc. Methods and compositions for treating autoimmune disease
EP2198050A1 (en) 2007-09-14 2010-06-23 Asuragen, INC. Micrornas differentially expressed in cervical cancer and uses thereof
WO2009052386A1 (en) * 2007-10-18 2009-04-23 Asuragen, Inc. Micrornas differentially expressed in lung diseases and uses thereof
WO2009070805A2 (en) * 2007-12-01 2009-06-04 Asuragen, Inc. Mir-124 regulated genes and pathways as targets for therapeutic intervention
WO2009086156A2 (en) * 2007-12-21 2009-07-09 Asuragen, Inc. Mir-10 regulated genes and pathways as targets for therapeutic intervention
WO2009091934A1 (en) * 2008-01-17 2009-07-23 Sequenom, Inc. Single molecule nucleic acid sequence analysis processes and compositions
WO2009100430A2 (en) * 2008-02-08 2009-08-13 Asuragen, Inc miRNAs DIFFERENTIALLY EXPRESSED IN LYMPH NODES FROM CANCER PATIENTS
WO2009154835A2 (en) * 2008-03-26 2009-12-23 Asuragen, Inc. Compositions and methods related to mir-16 and therapy of prostate cancer
WO2009126726A1 (en) * 2008-04-08 2009-10-15 Asuragen, Inc Methods and compositions for diagnosing and modulating human papillomavirus (hpv)
US8258111B2 (en) * 2008-05-08 2012-09-04 The Johns Hopkins University Compositions and methods related to miRNA modulation of neovascularization or angiogenesis
AR072999A1 (es) * 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US8691510B2 (en) 2008-11-07 2014-04-08 Sequenta, Inc. Sequence analysis of complex amplicons
US8748103B2 (en) 2008-11-07 2014-06-10 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
US9528160B2 (en) 2008-11-07 2016-12-27 Adaptive Biotechnolgies Corp. Rare clonotypes and uses thereof
US8628927B2 (en) 2008-11-07 2014-01-14 Sequenta, Inc. Monitoring health and disease status using clonotype profiles
EP2364368B1 (en) 2008-11-07 2014-01-15 Sequenta, Inc. Methods of monitoring conditions by sequence analysis
US9365901B2 (en) 2008-11-07 2016-06-14 Adaptive Biotechnologies Corp. Monitoring immunoglobulin heavy chain evolution in B-cell acute lymphoblastic leukemia
US9506119B2 (en) 2008-11-07 2016-11-29 Adaptive Biotechnologies Corp. Method of sequence determination using sequence tags
US20100179213A1 (en) * 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
DK3059337T3 (da) 2009-01-15 2019-07-22 Adaptive Biotechnologies Corp Adaptive immunity profiling og metoder til frembringelse af monoklonale antibodier
RU2014144463A (ru) 2009-06-25 2015-06-20 Фред Хатчинсон Кансэр Рисёч Сентер Способ измерения адаптивного иммунитета
US9043160B1 (en) 2009-11-09 2015-05-26 Sequenta, Inc. Method of determining clonotypes and clonotype profiles
US8906649B2 (en) 2010-09-27 2014-12-09 Janssen Biotech, Inc. Antibodies binding human collagen II
EP2621950A4 (en) 2010-09-27 2015-09-02 Janssen Biotech Inc ANTIBODIES FOR BINDING HUMAN COLLAGEN II
JP2014506789A (ja) 2011-02-03 2014-03-20 マーナ セラピューティクス インコーポレイテッド ｍｉＲ−１２４の合成模倣体
US10385475B2 (en) 2011-09-12 2019-08-20 Adaptive Biotechnologies Corp. Random array sequencing of low-complexity libraries
WO2013040251A2 (en) 2011-09-13 2013-03-21 Asurgen, Inc. Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease
US9279159B2 (en) 2011-10-21 2016-03-08 Adaptive Biotechnologies Corporation Quantification of adaptive immune cell genomes in a complex mixture of cells
EP3388535B1 (en) 2011-12-09 2021-03-24 Adaptive Biotechnologies Corporation Diagnosis of lymphoid malignancies and minimal residual disease detection
US9499865B2 (en) 2011-12-13 2016-11-22 Adaptive Biotechnologies Corp. Detection and measurement of tissue-infiltrating lymphocytes
DK2823060T3 (en) 2012-03-05 2018-05-28 Adaptive Biotechnologies Corp Determination of associated immune receptor chains from frequency-matched subunits
EP3091089B1 (en) 2012-05-08 2019-01-23 Adaptive Biotechnologies Corporation Method for measuring and calibrating amplification bias in multiplexed pcr reactions
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
US20160002731A1 (en) 2012-10-01 2016-01-07 Adaptive Biotechnologies Corporation Immunocompetence assessment by adaptive immune receptor diversity and clonality characterization
US10150996B2 (en) 2012-10-19 2018-12-11 Adaptive Biotechnologies Corp. Quantification of adaptive immune cell genomes in a complex mixture of cells
CA2892818A1 (en) * 2012-11-28 2014-06-05 Abwiz Bio, Inc. Preparation of gene-specific templates for the use in single primer amplification
WO2014144495A1 (en) 2013-03-15 2014-09-18 Abvitro, Inc. Single cell bar-coding for antibody discovery
US9708657B2 (en) 2013-07-01 2017-07-18 Adaptive Biotechnologies Corp. Method for generating clonotype profiles using sequence tags
AU2014323523B2 (en) 2013-09-20 2020-02-20 Bristol-Myers Squibb Company Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
WO2015134787A2 (en) 2014-03-05 2015-09-11 Adaptive Biotechnologies Corporation Methods using randomer-containing synthetic molecules
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
US10066265B2 (en) 2014-04-01 2018-09-04 Adaptive Biotechnologies Corp. Determining antigen-specific t-cells
CA2966201A1 (en) 2014-10-29 2016-05-06 Adaptive Biotechnologies Corp. Highly-multiplexed simultaneous detection of nucleic acids encoding paired adaptive immune receptor heterodimers from many samples
US10246701B2 (en) 2014-11-14 2019-04-02 Adaptive Biotechnologies Corp. Multiplexed digital quantitation of rearranged lymphoid receptors in a complex mixture
EP3224384A4 (en) 2014-11-25 2018-04-18 Adaptive Biotechnologies Corp. Characterization of adaptive immune response to vaccination or infection using immune repertoire sequencing
US11047008B2 (en) 2015-02-24 2021-06-29 Adaptive Biotechnologies Corporation Methods for diagnosing infectious disease and determining HLA status using immune repertoire sequencing
WO2016161273A1 (en) 2015-04-01 2016-10-06 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
US10428325B1 (en) 2016-09-21 2019-10-01 Adaptive Biotechnologies Corporation Identification of antigen-specific B cell receptors
KR102721137B1 (ko) 2017-05-30 2024-10-25 브리스톨-마이어스 스큅 컴퍼니 항-lag-3 항체 또는 항-lag-3 항체 및 항-pd-1 또는 항-pd-l1 항체를 포함하는 조성물
CA3060984A1 (en) 2017-05-30 2018-12-06 Bristol-Myers Squibb Company Treatment of lag-3 positive tumors
US11761963B2 (en) 2017-09-27 2023-09-19 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-CD200 therapy
US11254980B1 (en) 2017-11-29 2022-02-22 Adaptive Biotechnologies Corporation Methods of profiling targeted polynucleotides while mitigating sequencing depth requirements
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57501692A (enExample) 1980-09-24 1982-09-16
ATE53862T1 (de) 1982-01-22 1990-06-15 Cetus Corp Verfahren zur charakterisierung von hla und die darin benutzten cdns-testmittel.
US4582788A (en) * 1982-01-22 1986-04-15 Cetus Corporation HLA typing method and cDNA probes used therein
US4683194A (en) * 1984-05-29 1987-07-28 Cetus Corporation Method for detection of polymorphic restriction sites and nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
CA1284931C (en) 1986-03-13 1991-06-18 Henry A. Erlich Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids
CA1338457C (en) 1986-08-22 1996-07-16 Henry A. Erlich Purified thermostable enzyme
US5130238A (en) * 1988-06-24 1992-07-14 Cangene Corporation Enhanced nucleic acid amplification process
US5508178A (en) * 1989-01-19 1996-04-16 Rose; Samuel Nucleic acid amplification using single primer
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5595891A (en) * 1990-07-19 1997-01-21 Behringwerke Ag Method for producing a polynucleotide for use in single primer amplification
AU662148B2 (en) * 1991-04-10 1995-08-24 Scripps Research Institute, The Heterodimeric receptor libraries using phagemids
ATE152180T1 (de) * 1992-07-31 1997-05-15 Behringwerke Ag Verfahren zur einführung von definierten sequenzen am 3' ende von polynukleotiden
FR2724934B1 (fr) * 1994-09-26 1997-01-24 Bio Merieux Oligonucleotide chimere et son utilisation dans l'obtention de transcrits d'un acide nucleique
US5882856A (en) * 1995-06-07 1999-03-16 Genzyme Corporation Universal primer sequence for multiplex DNA amplification
US5962271A (en) * 1996-01-03 1999-10-05 Cloutech Laboratories, Inc. Methods and compositions for generating full-length cDNA having arbitrary nucleotide sequence at the 3'-end
CA2303299C (en) 1997-09-12 2016-02-23 Exiqon A/S Oligonucleotide analogues
GB9817055D0 (en) 1998-08-05 1998-09-30 Medical Res Council Reverse transcription and amplification processes and primers therefore
US6465182B1 (en) * 1999-04-29 2002-10-15 The Regents Of The University Of California Comparative fluorescence hybridization to oligonucleotide microarrays
JP2003505034A (ja) 1999-07-19 2003-02-12 ケンブリッジ・ユニバーシティ・テクニカル・サービシーズ・リミテッド 存在量の少ない核酸配列を増幅する方法および該方法を行うための手段
JP2003527087A (ja) * 1999-08-13 2003-09-16 イェール・ユニバーシティ バイナリーコード化配列タグ
CA2384838C (en) * 1999-09-13 2006-07-18 Nugen Technologies, Inc. Methods and compositions for linear isothermal amplification of polynucleotide sequences
WO2001055454A1 (en) 2000-01-28 2001-08-02 Althea Technologies, Inc. Methods for analysis of gene expression
WO2002048401A2 (en) * 2000-12-11 2002-06-20 Alexion Pharmaceuticals, Inc. Nested oligonucleotides containing hairpin for nucleic acid amplification

Also Published As

Publication number Publication date
US7306906B2 (en) 2007-12-11
EP1436404A4 (en) 2006-07-05
CA2460639C (en) 2013-07-16
CY1109828T1 (el) 2014-09-10
EP1436404A2 (en) 2004-07-14
CA2460639A1 (en) 2003-03-27
PT1436404E (pt) 2009-12-16
JP2005503802A (ja) 2005-02-10
ES2336433T3 (es) 2010-04-13
ATE448320T1 (de) 2009-11-15
DK1436404T3 (da) 2010-03-08
DE60234369D1 (de) 2009-12-24
JP2009089716A (ja) 2009-04-30
EP1436404B1 (en) 2009-11-11
AU2002341752B2 (en) 2008-04-03
JP5107274B2 (ja) 2012-12-26
US20040072164A1 (en) 2004-04-15
WO2003025202A2 (en) 2003-03-27
WO2003025202A3 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
JP5107274B2 (ja) 操作されたテンプレートおよび単一プライマー増幅におけるそれらの使用
JP2012157371A (ja) 人工テンプレートおよび単一プライマー増幅におけるその使用
AU2002341752A1 (en) Engineered templates and their use in single primer amplification
USRE41365E1 (en) Nested oligonucleotides containing a hairpin for nucleic acid amplification
JP4289443B2 (ja) Ｐｃｒの過程でｄｎａ断片の増幅を抑制する方法
US5514568A (en) Enzymatic inverse polymerase chain reaction
JP2009508495A (ja) ｃＤＮＡライブラリー調製
JP5758125B2 (ja) 抗体ライブラリーを作製およびスクリーニングするための新規な方法
JP2003535587A (ja) 低温感受性変異体ｄｎａポリメラーゼ
JPH05508313A (ja) ポリヌクレオチドの増幅
KR100987352B1 (ko) 비특이 증폭을 감소시킬 수 있는 ｐｃｒ용 프라이머 및이를 이용한 ｐｃｒ 방법
US20090011471A1 (en) Engineered plasmids and their use for in situ production of genes
JP6004423B2 (ja) 遺伝子連結法およびそれを用いた単鎖抗体作製方法
Class et al. Patent application title: Orthogonal Amplification and Assembly of Nucleic Acid Sequences Inventors: George M. Church (Brookline, MA, US) Sriram Kosuri (Cambridge, MA, US) Sriram Kosuri (Cambridge, MA, US) Nikolai Eroshenko (Boston, MA, US) Assignees: President and Fellows of Harvard College
KR20120105640A (ko) 다중 타겟 위치의 단일 핵산서열로의 어셈블리 방법
US20030104417A1 (en) Template-mediated, ligation-oriented method of nonrandomly shuffling polynucleotides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20081027

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090127

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20091217

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100105

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130115

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130115

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees